Zika virus vaccine

Patent metadata

Field	Value
Publication number	US-12496335-B2
Application number	US-202318338612-A
Country	US
Kind code	B2
Filing date	Jun 21, 2023
Priority date	Feb 17, 2016
Publication date	Dec 16, 2025
Grant date	Dec 16, 2025

Abstract

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Zika virus or a disorder related to such an infection. In particular, the present invention concerns a Zika virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

First claim

The invention claimed is:

1 . An artificial nucleic acid comprising at least one coding region encoding at least one polypeptide comprising Zika virus envelope protein (E), wherein the artificial nucleic acid is a mRNA comprising, in 5′ to 3′ direction, the following elements:
a) a 5′-CAP structure;
b) the at least one coding region comprising a modified nucleic acid sequence encoding the at least one polypeptide comprising Zika virus envelope protein (E), wherein the at least one polypeptide comprises an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 540, 537, 545 or 549, wherein the at least one coding region comprises a nucleic acid sequence identical to the polypeptide coding region of any one of SEQ ID NOs: 3300, 3297, 5505, 5513 or 5517 or a sequence at least 80% identical to the polypeptide coding region of any one of SEQ ID NOs: 3300, 3297, 5505, 5513 or 5517;
c) a heterologous 3′-UTR element comprising a nucleic acid sequence; and
d) a poly (A) sequence comprising 10 to 200 adenosine nucleotides.

2 . The artificial nucleic acid according to claim 1 , wherein (b) the at least one coding region comprises an amino acid sequence at least 95% identical to SEQ ID NO: 537, wherein the at least one coding region comprises a nucleic acid sequence identical to the polypeptide coding region of SEQ ID NO: 3297 or a sequence at least 80% identical to the polypeptide coding region of SEQ ID NO: 3297.

3 . The artificial nucleic acid of claim 1 , further comprising at least one heterologous 5′ untranslated region (UTR) element.

4 . The artificial nucleic acid of claim 3 , wherein the at least one heterologous 5′-UTR element comprises a nucleic acid sequence, which is derived from the 5′-UTR of a TOP gene.

5 . The artificial nucleic acid of claim 1 , wherein the artificial nucleic acid comprises at least one histone stem-loop.

6 . The artificial nucleic acid of claim 1 , wherein the at least one encoded polypeptide comprises at least one signal sequence.

7 . The artificial nucleic acid of claim 1 , wherein the G/C content of the at least one coding region is increased compared to the G/C content of a reference RNA encoding the at least one polypeptide.

8 . The artificial nucleic acid of claim 1 , wherein the at least one heterologous 3′-UTR element comprises a nucleic acid sequence derived from a 3′-UTR of a gene selected from the group consisting of an albumin gene, an α-globin gene, a β-globin gene, a tyrosine hydroxylase gene, a lipoxygenase gene, and a collagen alpha gene.

9 . The artificial nucleic acid of claim 1 , wherein the at least one polypeptide comprises a stem region of the Japanese encephalitis virus E protein.

10 . The artificial nucleic acid of claim 1 , wherein the modified nucleic acid sequence comprises a nucleotide with a base modification selected from pseudouridine or 1-methyl-pseudouridine.

11 . The artificial nucleic acid of claim 10 , wherein the modified nucleic acid sequence comprises a 1-methyl-pseudouridine.

12 . The artificial nucleic acid according to claim 1 , wherein (b) the at least one coding region comprises an amino acid sequence at least 95% identical to SEQ ID NO: 537, wherein the at least one coding region comprises a nucleic acid sequence identical to the polypeptide coding region of SEQ ID NO: 3297 or a sequence at least 85% identical to the polypeptide coding region of SEQ ID NO: 3297.

13 . The artificial nucleic acid according of claim 12 , wherein the at least one polypeptide comprises the amino acid sequence according to SEQ ID NO: 537.

14 . A composition comprising at least one artificial nucleic acid as defined by claim 1 and a pharmaceutically acceptable carrier.

15 . The composition according to claim 14 , wherein the at least one artificial nucleic acid is complexed at least partially with a cationic or polycationic compound and/or a polymeric carrier.

16 . The composition according to claim 15 , wherein the at least one artificial nucleic acid is complexed at least partially with a cationic compound.

17 . The composition according to claim 16 , wherein the cationic compound comprises a cationic lipid.

18 . A kit or kit of parts comprising the artificial nucleic acid according to claim 1 , optionally a liquid vehicle for solubilising, and optionally technical instructions providing information on administration and dosage of the components.

19 . A method of treating a subject with, or protecting a subject from, an infection with Zika virus or a disorder related to an infection with Zika virus comprising administering to said subject the artificial nucleic acid according to claim 1 .

20 . An artificial nucleic acid comprising at least one coding region encoding at least one polypeptide comprising Zika virus envelope protein (E), wherein the artificial nucleic acid is a mRNA comprising, in 5′ to 3′ direction, the following elements:
a) a 5′-CAP structure,
b) the at least one coding region comprising a modified nucleic acid sequence encoding the at least one polypeptide comprising Zika virus envelope protein (E), wherein the at least one polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO: 537, wherein the at least one coding region comprises a nucleic acid sequence identical to the polypeptide coding region of SEQ ID NO: 3297 or a sequence at least 95% identical to the polypeptide coding region of SEQ ID NO: 3297,
c) a heterologous 3′-UTR element comprising a nucleic acid sequence, and
d) a poly (A) sequence comprising 10 to 200 adenosine nucleotides.

Assignees

• CureVac SE
• Sanofi Pasteur

Inventors

• Petsch Benjamin
• Jasny Edith
• Girerd-Chambaz Yves

Classifications

• C07K14/005

  from viruses · CPC title

• A61K39/385

  Haptens or antigens, bound to carriers · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61K47/646

  the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines · CPC title

• A61K47/6455

  Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids · CPC title